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Disclaimer 
This report was sponsored by the European Medicines Agency in the context of the Benefit-risk 
methodology project and the views expressed are those of the authors. An opportunity for public 
consultation will be given in the future prior to the adoption of a final position. This report is the 
intellectual property of the European Medicines Agency. 
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EXECUTIVE SUMMARY 
This report summarises the experience of five field tests in European Agencies of quantitative benefit-
risk modelling. Participating agencies included AFSSAPS in France, MHRA in the United Kingdom, MEB 
in the Netherlands, PEI in Germany and AEMPS in Spain. Each agency chose a drug that was currently 
under review by the CHMP. We engaged between four and six people in each agency in a facilitated 
one-day workshop to construct, on-the-spot, a benefit-risk model of the drug and its comparators. 
Participants included clinical assessors and experts who were knowledgeable about the drug being 
modelled. Questionnaires filled out by participants at the start and end of the workshop consisted of 20 
questions that provided a comparison of current processes with how the modelling session could 
contribute to benefit-risk assessments. 
The eight-stage PrOACT-URL framework (Problem formulation, Objectives, Alternatives, Consequences, 
Trade-Offs, Uncertainties, Risk Attitude and Linked Decisions), adapted for use in drug benefit-risk 
assessment, provided an informal agenda for each of the five meetings. Using assessment reports at 
different stages of writing and other data sources, participants were able to construct Effects Trees 
that showed the organisation of favourable and unfavourable effects. For each drug, an Effects Table 
provided definitions of the criteria, showed upper and lower limits of scoring scales, the units in which 
the data for each criterion were expressed and the type of value function. The latter relates the 
measured input data to the clinical relevance of the scale range, thus enabling the input data to be 
transformed into preference values. 
Data were entered into the computer model, and judgements made about the relative utilities of the 
effects. These judgements were expressed as ‘swing weights’ that compared the clinical relevance of 
the ranges of the measurement scales. These weights acted as scale constants that equated the units 
of preference across all the preference scales in the model. With all input data converted into 
preference values, it was possible to examine the benefit-risk balance of each drug. Extensive 
sensitivity analyses enabled participants to see how that balance changed, if at all, with different 
judgements about clinical relevance, or with different input data (such as the pessimistic limits of a 
confidence interval). 
Two graphical representations of the final results proved to be the most useful displays. The first was 
the Added-Value graph, a stacked bar graph that showed the overall added value for the drug, and 
another for each comparator. Added value was defined as the benefit from all the favourable effects, 
and the absence of severity of all the unfavourable effects. The second graph was the Difference 
Display, which showed the difference between the drug and a single comparator (e.g., the placebo) for 
each effect, favourable and unfavourable. This graph showed the weighted difference of the preference 
values, so it accommodated both the data and clinical judgements about all the effects.  
Analysis of the comparison between pre- and post-questionnaires showed, on average, favourable 
views of the modelling session for all 20 questions. Overall, this report provides ample evidence for the 
success of the facilitated modelling sessions and it demonstrates the feasibility of quantitative 
modelling for determining the benefit-risk balance. 
Note: At this writing, any detailed information of the five drugs is considered confidential, so no data 
about these drugs can be reported. A hypothetical rheumatoid arthritis drug, Drug X, will be used here 
to illustrate the graphical displays that were found useful in the modelling of the five drugs. This report 
will be revised to give specific details of each of the models when the confidentiality status will be 
changed. 
These five field tests were done in parallel to the ongoing assessment process without affecting it. 
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Benefit-risk methodology project 
Work package 3 report: Field tests 
1.  Introduction 
The main objective of the EMA Benefit-Risk Methodology Project 1 is the development and testing of 
tools and processes for balancing multiple benefits and risks, which can be used as an aid to informed, 
science-based regulatory decisions about medicinal products. The project consists of five consecutive 
work packages. The first work package reported on the current practice of benefit-risk assessment in 
the centralised procedure for medicinal products in the EU regulatory network 2. The report of that 
work package described processes at the six participating agencies, all of which effectively serve the 
centralised procedure, but in different ways. Interviews with 55 staff of the agencies revealed 
substantial differences in the meanings of ‘benefit’ and ‘risk’, particularly for the latter. Recognising 
that a science of benefit-risk decision making requires agreed definitions, we recommended that the 
EMA’s assessment reports be structured to distinguish favourable from unfavourable effects of 
medicines, and to separate out the uncertainties associated with those effects. This was adopted in the 
autumn of 2009, with the result that the benefit-risk sections of Assessment Reports are more 
comprehensive and clear, and the justification for the assessment of the benefit-risk balance is made 
explicit. 
The second work package examined the applicability of current tools and processes for assessing the 
benefit-risk balance 3. We found that only decision theory can explicitly incorporate the three key 
ingredients of all benefit-risk assessments: data for the favourable and unfavourable effects, 
uncertainties about those effects, and clinical judgements about the desirability, severity and relevance 
of the effects. However, we recognised that support to decision theory modelling might be desirable 
from five other approaches: probabilistic simulation, Markov processes, Kaplan-Meier estimators, 
QALYs and conjoint analysis. 
Support for our view about combining methodologies came in the summer of 2010 when four post-
graduate students from the London School of Economics studying operational research and decision 
sciences were given the European Public Assessment Reports (EPARs) of 14 drugs that had already 
completed the centralised assessment procedure and were asked to use any models they found 
suitable for quantitative modelling of the benefit-risk balance. Their project reports showed that a 
variety of model combinations were used, but all were based on decision theory, as can be seen in 
Table 1. 
The experiences of the students lent support to the next phase of our project: work package 3, whose 
purpose was to field test models for drugs that were currently under review by the CHMP. The present 
report gives our findings from this field research.
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Table 1: The four drugs modelled by LSE students and the type of model for each indication. 
 
Product Indication Method 
Acomplia Obesity MCDA 
Cimzia Rheumatoid Arthritis MCDA + probabilistic simulation 
Sutent Gastrointestinal cancer Decision Tree + Markov model 
Tyverb Breast cancer MCDA + probabilistic simulation 
 
 
2.  Method 
Five European Agencies participated in the field research, as shown in Table 2. We asked each agency 
to choose a drug that is currently under scrutiny by the CHMP, and to schedule a time for our visit to 
suit their schedule and availability of assessors and experts for a one-day meeting. We held a 
teleconference with some or all of the participants to explain the purpose of our visit and the 
preparation that would be helpful. We indicated that the session would be conducted as a decision 
conference 4, a facilitated workshop to construct, on-the-spot, a benefit-risk model of the drug and its 
comparators. Questions and discussion followed, and we established that it was important for 
participants to represent a diversity of views about the drug. About a week before each meeting, we 
sent email reminders to all participants, which included an attachment describing the decision 
conferencing process. 
The facilitators read the relevant assessment reports, or their drafts, prior to each meeting. It was 
apparent that a multi-criteria decision analysis (MCDA) model might be useful for each of the five 
cases. There are three key requirements for such models: 
1. To enable comparisons of dissimilar favourable and unfavourable effects to be compared (e.g., 
percentages of responders vs. mean QTc prolongation) each measured quantity is converted to 
a preference value on a 0 to 100 scale. 
2. The conversion for each effect can be accomplished by a linear or non-linear translation, called 
a ‘value function’, which is an assessment of the clinical relevance of various levels of the 
measured quantity. 
3. The units for the preference value scales are equated through a process known as ‘swing 
weighting’, which requires judgements of the clinical relevance of scale differences. This 
enables weighted effects to be summed to give an overall benefit-risk balance. 
Each meeting started at about 9am and continued with breaks and lunch until about 4 or 5pm. The 
meetings were attended by between four and six people, always including clinical assessors and 
experts in the disease state. The day began with introductions and a re-iteration of today’s research 
purpose: to determine whether or not a quantitative model could help assessors in their task of 
preparing an assessment report. We handed out a questionnaire consisting of 20 questions about the 
Agency’s existing processes for assessing the benefit-risk balance of a drug. Each question was 
accompanied by a 7-point scale on which the participant could indicate the extent of their 
disagreement or agreement with the question. 
 
Benefit-risk methodology project   
EMA/653117/2011  Page 5/29
 
 
Benefit-risk methodology project   
EMA/653117/2011  Page 6/29
 
Table 2: The five agencies participating in the field research and the stage of assessment. 
  
 
Agency 
Date 
of visit 
 
Stage of Assessment 
AFSSAPS 29 Oct 10 pre-Day 80 
MHRA 22 Nov 10 pre-Day 80 
MEB 20 Dec 10 post-Day 80 
PEI 20 Jan 11 CHMP Overview and 
Request for Supple-
mentary Information 
AEMPS 9 Feb 11 Day 150 Joint Response 
Assessment Report 
 
 
To start the modelling process, the facilitator briefly explained the foundations of decision theory 5, 
whose axioms of coherent preference lead to the expected utility model (briefly explained here in the 
Results section). Recognising that people’s preferences are not always coherent, particularly in 
situations of uncertainty 6, the facilitator explained that today we would use decision theory to help 
construct a coherent view of the drug’s benefit-risk balance. Thus, coherent views are not assumed at 
the start, but should emerge by the end of the day. 
2.1.  Problem formulation 
The PrOACT-URL framework 7 presented in Work Package 2 (and reproduced here in Appendix A) 
guided the process of developing the model, though it did not act as a rigid agenda—only those stages 
and questions that the facilitator felt would be helpful to the group were covered. Most of the questions 
in stage 1, PrOBLEM, were answered: some drugs are chemical entities while others are biological; 
some diseases are very serious, others less so; some involve potentially fatal side effects while others 
do not; one has already been approved for adults and an indication for children is being sought; one is 
an orphan drug; all differ in the extent of unmet medical need, and so forth. For all five groups, the 
problem was framed as involving both multiple objectives—favourable and unfavourable effects—and 
their uncertainties. 
As part of the context, the group explained where they are now in assessing the drug. For one drug, 
only an incomplete draft of the Day 80 Assessment Report had been prepared, and for another the 
joint Day 150 was available. The assessment by the other three groups fell between the Day 80 and 
Day 150 reports. In all cases, information from the dossier could have been or was accessed. 
At this point in the process, the computer, with Hiview1 software loaded, was projected so all 
participants could see the model being created at each step. 
2.2.  Alternatives (options) 
Alternatives were usually considered next. In three cases the drug was compared only to a placebo. In 
addition to the placebo, two comparators were included for one drug, and two possible doses were 
considered for another. As these alternatives were given in the dossier and assessment reports, this 
stage of the modelling was completed very quickly. 
                                              
1 Hiview was initially developed at the London School of Economics to enable application of decision theory to problems 
involving multiple objectives and uncertainty. It is now developed by Catalyze Ltd, and available at www.catalyze.co.uk.  
2.3.  Objectives and criteria 
The same could not be said for identifying and defining the criteria in the OBJECTIVES stage. Part of 
the problem is that a great many effects, favourable and unfavourable, are mentioned in the reports, 
but not all of them are relevant to the task of balancing benefits and risks. For example, quality of 
sufficient standard was assumed for all the five cases, and tolerable adverse events were excluded. 
Thus, the process has to begin by eliminating criteria that are assumed to be satisfied, or can be 
assumed to have little or no appreciable effect on the benefit-risk balance. Once agreement was 
reached, the group constructed an ‘Effects Tree’. An example, shown in Figure 1, gives an Effects Tree 
for ‘Drug X’, a hypothetical rheumatoid arthritis drug to be used in combination with methotrexate. 
After a ‘short list’ of criteria had been agreed, the next steps were to define the criteria and 
operationalise measurement scales for them, with clearly defined units. This had, of course, already 
been done, or the dossier would be considered incomplete. However, finding precise definitions and 
then defining the measurement scale was usually not easy because this information does not appear in 
just one place; it is scattered throughout the available reports. In addition, the definitions are often 
assumed by the assessors, who are familiar with their disciplines, and whose understanding of these 
issues is often implicit. Precise definitions of measurement scales were often missing in the assessment 
reports, and required web searches to discover their exact meaning.  
 
 
 
 
Figure 1: An Effects Tree for Drug X. 
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Next, the group established two points on each scale that encompassed the range of data, including 
uncertainties in the data. Thus, for the average response rate of favourable effects, some scales 
extended from 0 to 100 percent, while for incidence of adverse events that were rare, a scale might 
extend only from 0 to 20 percent. For scales of numbers of serious adverse events requiring 
hospitalisation, the range might be very small, say from 0 to 5 SAEs per person per year. These ranges 
were implicit in the available data, so some effort was needed to make them explicit. The reason for 
establishing these ranges was to provide meaningful limits for subsequent judgements of trade-offs 
between the criteria.  
2.4.  Consequences 
Nowhere in any report did we find summaries such as those suggested by the CONSEQUENCES stage 
of PrOACT-URL, so, again, the group had to engage in considerable searching to provide both the 
qualitative and quantitative data. Time did not permit the creation of a consequence table, but 
measurable data for most of the criteria were identified. Occasionally, we suggested a criterion for 
which informed judgements could be made directly on preference scales, for example, the criterion 
“Potential for serious adverse events” was added for one of the five drugs even though no SAEs had as 
yet been observed. 
Criterion definitions, measurement units and ranges were entered into the computer program as that 
information for each alternative was identified, followed by entering measured data obtained from the 
clinical studies. In preparing reports of each decision conference we summarised all this information in 
an Effects Table like the one shown here for Drug X, Table 3.  
While the data for a criterion were being considered, the facilitator asked questions to determine how 
those data were considered clinically to ensure that the conversion from measured input data to 
preference values would capture the way regulators think about clinical relevance. Generally, direct 
linear scales were found to be appropriate for favourable effects (the higher the effect, the more the 
preference), and inverse linear scales for unfavourable effects (the more severe the effect, the less the 
preference). However, there were some exceptions. An example is shown in Figure 2, a value function 
for Drug X. No malignancies is most preferred, so it scores 100, but the function declines quickly, with 
0.5% at a preference value of 50, 1% at 20, 1.5% at 5 and 2 or more at zero. 
 
 
 
Figure 2: A value function for the proportion of patients developing at least one malignancy. 
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Table 3: The Effects Table for Drug X. 
 
Name Description 
Fixed 
Lower† 
Fixed 
Upper† 
Units Placebo 
Drug X 200 
mg+MTX 
Drug X 
400mg+MTX 
ACR 20 
Proportion of patients achieving ACR* 
20 at week 24 
0 100 % 11.7 58.2 59.6 
ACR 50 
Proportion of patients achieving ACR* 
50 at week 24 
0 100 % 5.8 34.8 36.6 
ACR 70 
Proportion of patients achieving ACR* 
70 at week 24 
0 100 % 2.4 18.8 16.1 
F
a
v
o
u
r
a
b
l
e
 
E
f
f
e
c
t
s
 
mTSS 
Mean amount of progression of joint 
damage in hands and feet at week 
52** 
0 10 
Change 
Score±SD 
2.8±7.8 0.4±5.7 0.0±4.8 
Infections 
Proportion of patients experiencing 
infections & infestations 
70 80 
No. per 
100 pt-yrs 
72.13 79.88 76.62 
SAEs 
Proportion of patients experiencing 
musculoskeletal & connective tissue 
disorders 
25 60 
No. per 
100 pt-yrs 
57.05 28.39 25.88 
Deaths Proportion of patient deaths 0 3 % 0.15 0.42 0.97 
Tuberculosis 
Number of patients contracting 
tuberculosis 
0 30 Number 0 5 28 
U
n
f
a
v
o
u
r
a
b
l
e
 
E
f
f
e
c
t
s
 
Malignancies 
Proportion of patients developing at 
least one malignancy 
0 2 % 0.9 1.9 1.4 
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2.5.  Trade-offs 
At this stage in the analysis, the model included sufficient information for all input data to be 
translated into preference value scales that extended from 0 to 100. The next step, swing-weighting, 
ensured that the units across all the preference scales were equivalent. As an analogy, both Celsius 
and Fahrenheit temperature scales include 0 to 100 portions. However, the differences in temperature 
are not equivalent: five units of measurement on a Celsius scale are equivalent to nine units on a 
Fahrenheit scale. To establish the comparability of preference among all the criteria for a given Effects 
Tree, we asked this question: “How large is the difference between the 0 and 100 points on this scale, 
and how much do you care about that difference, compared to the 0-to-100 difference on this other 
scale.” The first part of the questions is a matter of fact, the second of clinical judgement. For 
example, for the proportion of malignancies, shown in Figure 2, the 0-to-100 difference corresponds to 
2% of patients developing at least one malignancy, but how much that difference is considered to be 
clinically relevant is a matter of judgement. It is both the factual difference and its importance that are 
compared, criterion-to-criterion. 
This swing-weighting process was first carried out within a cluster of criteria, with the largest swing 
that mattered assigned a weight of 100. The process was then repeated for the remaining clusters. 
Next, comparisons across clusters compared the 100-weighted criteria from each cluster. For example, 
the swings on the three ACR criteria were first compared, two at a time (paired-comparisons) to 
establish the largest swing, which in this case was the ACR 70 criterion, not surprisingly since that 
would be the best outcome of the three, even though ACR 20 was the primary end point. Swings on 
the other two ACR criteria were compared, one at a time to the ACR 70 swing, with weights assigned 
as percentages of that swing, ACR 50 at 70 and ACR 20 at 40. ACR 70’s swing of 100 was then 
compared to the swing on mTSS, which was judged to be equivalent, so was also assigned a 100. 
At this point, the three ACR scores summed to 210, but since a degree of double counting was evident 
in the definitions of the ACR scales, the facilitator asked if the 210 figure should be reduced compared 
to the 100 on the mtSS score. However, the assessors agreed that the approximate two-to-one ratio 
between ACR and mTSS appeared to them to be realistic, so the sum was retained. Ideally, the ACR 
criterion would be sub-divided into non-overlapping segments, but the facilitator decided it was better 
to accept the definitions of the favourable effects as they were to appear in the assessment report. By 
adding the swing weight of 100 to the ACR total, the final total for the favourable effects was 310. 
The swings on all five unfavourable effects were compared by first identifying the largest swing 
(Deaths) and assigning it 100, followed by paired comparisons of remaining four criteria. Consistency 
checks on the sums of the swing weights, which indicate the added degrees of safety if the undesirable 
effect is absent, enabled the assessors to check the consistency of their assessments, and make 
changes if necessary to ensure the realism and consistency of their judgements. The final total swing 
weight sum on the unfavourable effects came to 231. Thus, the ratio of weights on the favourable to 
unfavourable effects was 310 to 231, which when normalised so the weights sum to 100 becomes 57.3 
and 42.7. 
Finally, the ACR 70 and Deaths criteria, each of which had been weighted at 100, were compared. The 
assessors found it difficult to make this judgement, but after discussion agreed they were about equal. 
This final judgement, along with the other judgements about criterion weights, ensured the 
equivalence of the units of weighted scores, thereby providing a common scale on which both 
favourable and unfavourable effects could be displayed. 
At this point, sufficient information was available for the computer to make the necessary calculations 
and display the results. As will be seen in the Results section, various graphical displays showed the 
overall results and the contribution of each criterion to the overall balance of effects.  
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2.6.  Uncertainty 
Uncertainties in the data were explored with sensitivity analyses. Changing the relative weights on the 
favourable versus unfavourable effects was usually examined first. Changing weights on other criteria 
followed, and the computer carried out an analysis on all the weights to see which ones mattered most 
to the benefit-risk balance. 
Sensitivity analyses were also carried out with input scores. Ranges of confidence intervals on key 
effects provided changes to the base-case model enabling exploration of optimistic and pessimistic 
perspectives about the data. In a few cases, changes in both input scores and weights provided a way 
for exploring possible future scenarios. For example, it was possible to see how easy or difficult it was 
to tip the effects balance with different judgements; this gave some indication of the model’s 
robustness. When differences in judgements arose from participants (usually about weights), 
sensitivity analyses provided a way of determining whether or not the overall balance of effects 
remained positive or negative. In some cases, the group engaged in ‘what-if’ analyses to see how the 
benefit-risk balance might change in light of new information or alternative perspectives about the 
clinical relevance of some criteria, i.e., scenarios representing possible future developments. These 
were explored by changing various combinations of revised scores and weights. 
2.7.  Risk attitude 
Many of the judgemental inputs could be considered as expressions of participants’ risk attitudes. This 
could, of course, be different depending on the perspective being taken: regulator, clinician or patient, 
for example. By assuming different roles, participants for some drugs explored how different 
perspectives could affect the overall balance. This could involve changing a non-linear value function, 
or altering weights assigned to criteria. These changes could simulate different levels of risk tolerance 
as perceived by others. 
2.8.  Linked decisions 
Although this is a separate stage, the group discussed at various times during the construction of the 
model and in exploring results how consistent their thinking and judgements had been with past 
decisions, and what the implications of being so explicit might be for future decisions. 
By the end of the day, all five groups completed building and exploring the model. We then 
administered the same 20-item questionnaire, but this time they were asked to “reflect on the 
modelling session you have just experienced and on how it has impacted the way you can evaluate 
favourable and unfavourable effects and deal with uncertainty when working on an assessment 
report”. Later, we looked at the changes before and after the workshop to determine its possible added 
value to participants. 
Finally, we wrote a report of about 30 pages for each workshop and circulated it to all the participants 
as a full record of the session.  
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3.  Results 
Most of the results are shown graphically, which enhances exploration of the results and helps to 
deepen understanding. We begin with a graphical representation of the effects themselves, followed by 
stacked bar graphs of the benefit-risk balance and difference displays comparing the drug to the 
placebo. Sensitivity analyses show how varying weights on specific criteria over their full range from 0 
to 100 can affect the overall benefit-risk balance, and how combinations of changes in scores and 
weights can simulate possible future scenarios that could tip the benefit-risk balance. 
3.1.  Effects Tree 
Figure 1, above, gives the Drug X effects tree, four favourable effects and five unfavourable effects. 
However each of the trees developed for the five drugs we modelled is different; there is no standard 
tree, nor or there any criteria that are common to all trees, though Infections appears on four of the 
five trees. Also, serious adverse effects appears as a criterion in only two cases, though many of the 
unfavourable effects could be classed as SAEs. 
Deciding what criteria to include required careful discussion in each group because all Assessment 
Reports included more criteria than were eventually represented in the Effects Tree. Groups appeared 
to use an ‘Elimination-by-Aspects” (EBA) 8 strategy: criteria were rejected if they failed to satisfy 
certain minimum requirements for inclusion, such as no data available, effect not clinically important or 
significantly different statistically from the placebo, effect double-counts one already included, etc. 
3.2.  Criteria Definitions 
Writing a report following each workshop helped us to realise after the early sessions shortcomings in 
our understanding of the criteria that were included in each model. As a result, we included more 
information in the Effects Table in the later reports than in the earlier ones. We increasingly 
appreciated that providing clear and agreed definitions for all the criteria was a non-trivial step. 
Assessment reports often failed to provide either complete definitions or references to sources. This 
problem was particularly evident for scoring systems that were the province of the therapeutic area, 
and in a couple of cases it applied to the major endpoint. For example, web searches were required to 
find the exact definition of three favourable effects for two of the drugs. The List of Abbreviations in 
the assessment report for these three did no more than spell out the acronym and definitions were not 
given in the assessment reports. 
That said, we appreciated that the clinical assessors in each group were well aware of these scoring 
systems, and their current state of knowledge was quite sufficient to understand the clinical relevance 
of different levels of the scores and to assess preference scores or value functions. The precision 
required to express a precise definition remained a part of the assessors’ tacit knowledge. 
3.3 Added-Value Bars 
Results are calculated by applying two simple equations: expected utility and weighted utility. The 
expected utility rule, which we mentioned earlier is derived from the principles of coherent preference, 
specifies that the utility and probability should be multiplied for each possible consequence of an 
action, then summed over all those products to provide a guide to action: 
   Expected utility = Σ p×u 
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As applied to the benefit-risk assessment of a drug, first consider all the effects, favourable and 
unfavourable. Second, judge the relative value (or utility) of each effect. Third, assess the probability 
that the effect will occur. Fourth, apply the expected utility rule—multiply effect utility by its 
probability—for each effect and sum the products separately for the favourable effects and for the 
unfavourable effects. Finally, if the sum is positive, the favourable effects outweigh the unfavourable 
effects. 
That calculation assumes all effects can be assessed on a common value (or utility) scale. To achieve 
that commonality for all favourable and unfavourable effects, it is necessary to apply the weighted 
utility rule: 
   Weighted utility = Σ w×u 
The form is the same as the expected utility rule, but this time a weight multiplies the utility for each 
effect to ensure the comparability of the resulting weighted utilities. Since a weighted utility is a utility, 
it can then be multiplied by the probability associated with the effect. In this way, both types of 
equation are used to effect the benefit-risk balance. 
All five of the models reported here used both equations. In situations of no uncertainty, the weighted 
utility rule is the only calculation required; it forms the basis for multi-criteria decision analysis 
(MCDA). When uncertainty is involved and the outcomes of decisions can all be measured in a common 
unit (money, for financial decisions; QALYS for health outcomes), then only the expected utility 
calculation is required. But for drugs, balancing benefits with risks requires both equations, so these 
five models are a mixture of MCDA and expected utility. 
The first graphical result we looked at in each decision conference was a stacked bar graph, like the 
example in Figure 3. This shows the overall weighted preference values for Drug X at 200mg and 
400mg plus methotrexate, and the placebo. 
These graphs show the added value associated with the presence of favourable effects and the 
absence of unfavourable effects. That is, longer green bars indicate more benefit, and longer red bars 
show more safety.  
If a drug scored at the upper limit of the data range on all the favourable effects (therefore achieving 
preference values of 100 on all the favourable criteria) and exhibited no unfavourable effects at all 
(thus obtaining preference values of 100 on all the unfavourable effects), its overall score, however the 
criteria were weighted, would be 100. A similar line of reasoning for a ‘diabolical’ drug, one with no 
favourable effects and displaying the upper limit of the range for all unfavourable effects, would show 
an overall score of zero. With these extremes of 100 and zero defined, the drugs and placebos in our 
studies must score somewhere between these limits, depending on their added value from favourable 
effects and from their safety.  
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Figure 3: Added-value bar graphs for the favourable and unfavourable effects of Drug X 
200mg+MTX, Drug X 400mg + MTX, and for the placebo. Longer green bars indicate more 
benefit, longer red bars indicate more safety. 
 
In Figure 3, both doses show more added values for the favourable effects, with the 200mg dose 
better than the 400mg and both better than the placebo. Note that the beneficial effects for the 200mg 
dose are only slightly less than those for the 400mg dose, but the safety of the lower dose is better. 
A more detailed added-value bar graph for Drug X is shown in Figure 4. The favourable and 
unfavourable effects components are shown for each criterion. It is just possible to compare the 
segments with each other. For example, fewer deaths and tuberculosis cases are evident for the lower 
dose than the higher dose. 
 
 
 
 
Benefit-risk methodology project   
EMA/653117/2011  Page 14/29
 
 
 
Figure 4: Added-value bar graphs for all effects of Drug X 200mg+MTX, Drug X 400mg + 
MTX, and for the placebo. 
3.3.  Difference Display 
While the added-value bar graphs give a good overall comparison of the options, it is easier to see the 
difference in Figure 5. The criteria have been re-ordered on the basis of the weighted differences 
between the preference scores on the 400mg dose and the placebo. 
The first column of figures shows the cumulative weights, which are the products of the weights along 
each branch of the value tree, normalised so the products sum to one. The next column shows the 
difference in the original preference values assigned to the options on each criterion. The third column 
shows each difference multiplied by that criterion’s cumulative weight. It is this weighted difference 
that is based on the data, its clinical relevance expressed as a preference value, and the relative 
clinical importance of the criterion, as judged in the swing weights. In short the weighted differences 
show the clinical relevance of the evidence-based difference between the drug and the placebo. 
The right-extending green bars show the relative magnitude of those weighted differences that favour 
the drug, while the left-extending red bars favour the placebo. The cumulative sum of the green bars 
minus the lengths of the red bars comes to 6.0, the difference in overall scores shown in Figures 3 and 
4, 50 minus 44. Curiously, one of the unfavourable effects, SAEs, is better for the drug than the 
placebo. 
Figure 6 shows the differences between the two doses. Clearly, the main advantages of the lower dose 
are Tuberculosis and Deaths.  
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Figure 5: Difference display comparing Drug X 400mg + MTX with the placebo. 
 
 
 
 
Figure 6: Difference display comparing Drug X 400mg + MTX with Drug X 200mg + MTX. 
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3.4.  Sensitivity Analyses 
After seeing initial results, the groups examined the trade-off between favourable and unfavourable 
effects. Recall from Section 2.5, that the normalised weight on the unfavourable effects was 42.7, 
which is shown in the Cumulative Weight column of Figure 3, reproduced below in the left graph, and 
is also the position of the vertical red line in the right graph of Figure 7. The red line intersects the 
three lines above at the total scores of 44, 55 and 50 for the options, as displayed in the left graph. 
Those cumulative weights appear in the right column of the Added Value Bars in Figure 7. Increasing 
the weight on the Unfavourable Effects node would move the red line to the right, with the overall 
preference value for the 200mg drug increasing slightly but the overall value for the placebo increasing 
rather more, so that the placebo overtakes the drug at a cumulative weight of about 74. Decreasing 
the weight on the Unfavourable Effects results in the 400mg becoming most preferred (but only very 
slightly) when the cumulative weight reaches about 7. 
Thus, over a substantial range of trade-off judgements between the favourable and unfavourable 
effects, the 200mg dose remains most preferred. The model is quite robust to differences of opinion 
about the relative importance of these two classes of effects. 
 
 
Figure 7: Left, the Added-Value Bars for Drug X, as shown in Figure 3. Right, a sensitivity 
analysis showing the effects on the bars of changing the cumulative weight on the 
Unfavourable Effects node. The transition from yellow to the green background colour 
shows the point at which the drug would no longer be most preferred. 
 
Next, we usually showed sensitivity analysis graphs for weights on specific criteria, particularly those 
that were judged to be most important. Sometimes the graph showed that very large changes in 
weights would be required before the results would change in favour of a different option, but at other 
times only a small change would be required.  
Hiview includes a facility for carrying out sensitivity analyses all at once on the criteria. We always 
used this facility to gain an overall impression of the robustness of the model. Figure 8 shows the 
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analysis for Drug X. One participant was concerned about tuberculosis, for the cases had occurred 
mainly in high-incidence countries, so he felt that the weight on this criterion should be reduced. As 
can be seen in Figure 8, the weight would have to be increased by 5 to 15 points, but as the 
cumulative weight on Tuberculosis is already just 5.6, decreasing it by 5 points would effectively 
eliminate this criterion altogether, which was not deemed realistic by the other assessors. 
 
 
Figure 8: Sensitivity analyses on the cumulative weights separately for each of the effects 
for Drug X. The coloured bars indicate by how much the cumulative weight must change for 
a different option to become most preferred: green—more than 15 points, yellow—between 
5 and 15 points, red—less than 5 points. With no red bars, and only two yellow ones, 
substantial changes in weights would be required to change the overall most preferred 
option from the 200mg dose. 
3.5.  Scenario Analyses 
Although sensitivity analyses are one way of exploring the effects of uncertainty in the input data 
about weights on the overall benefit-risk balance, it is also possible to deal with uncertainty about the 
future by engaging in scenario analysis. For example, one drug posed a new challenge: its sole clinical 
study was based on very few patients because it was an orphan drug. The substantial lead in the 
drug’s overall score over the placebo, the largest difference of the five drugs studied, might not be so 
clear-cut if several of the mean scores for the favourable effects were overestimates, and if the 
percentage of patients experiencing infections were underestimated. So, we constructed a pessimistic 
future scenario by inputting to the computer all the lower limits of the 95% confidence intervals for the 
mean scores on the favourable effects, and the upper limit of percentages of infections, the only 
unfavourable effect of particular clinical concern. The consequence of these changes was to reduce the 
substantial lead to 5 points, though the model remained fairly robust to changes in weights. The only 
exception was that less than a five-point change in the cumulative weight for infections could tip the 
balance in favour of the placebo. 
Drug X provides another example of scenario analysis based on the input data. Note from Table 3 the 
range of plus or minus one standard deviation on the mTSS data. One standard deviation from the 
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mean in the optimistic direction for the placebo and in the pessimistic direction for the drug gives a 
clear overall result favouring the placebo over either drug dose. Clearly, the uncertainty in this one end 
point matters to the benefit-risk balance and would be worth further exploration, perhaps using 
probabilistic simulation. 
For another of the five drugs we studied, the consequences of two changes were explored by the 
group. First, the weight on Potential for SAEs was dropped to zero because none had been observed in 
the clinical studies. This substantially increased the preference values for the higher dose of the drug 
over the placebo, which demonstrated the potential effectiveness of the drug. 
These analyses showed the ease with which other scores and weights can be used to explore the 
effects of uncertainty about the future performance of the drug. 
3.6.  Questionnaire Results 
Nineteen participants completed both the pre- and post-questionnaires. The median number of positive 
differences for each participant at the end of the workshop was 14 (out of 20 questions). The average 
change scores were positive for all 20 questions and the overall average change was 1.12 (on a 7-
point scale from strongly disagree to strongly agree). 
The seven highest differences, and their average change scores in parentheses, were that the 
modelling process: 
1. can easily test different perspectives for their impact on the results (2.95), 
2. helps us explore how the overall balance is affected by a reduction or increase in uncertainty 
(2.47), 
3. helps me to see the impact of uncertainties on the benefit-risk balance (1.84), 
4. has an overt and clear structure (1.42), 
5. helps us combine data about value and uncertainty into an overall balance between favourable 
and unfavourable events (1.42), 
6. helps us make our assumptions, multiple objectives and trade-offs explicit (1.37), and 
7. helps us anticipate the outcome of possible issues of concern (e.g. less efficacy or more severe 
side effects) (1.21). 
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4.  Discussion 
The positive change scores show that all the participants who filled out both questionnaires found 
much that is useful in the modelling process. It is important to recognise the three elements that 
contributed to the favourable experiences: impartial facilitation, a structured quantitative model 
developed on-the-spot, and a group process that enabled everyone to contribute in a context of peer 
review. This is very different from the back-room modelling that typically attends statistical analyses: 
data turned over to an individual statistician, who develops a model that expresses results in summary 
form, which are then given in assessment reports as measures of central tendency, confidence 
intervals and significance levels. The goal of that type of modelling is to develop as far as possible 
objective statements in the form of valid statistical inferences about effects. 
The goal in decision modelling is to extend the statistical analysis to include the effects of uncertainty 
and value judgements on the overall benefit-risk effectiveness of drugs. Favourable and unfavourable 
effects are based on facts; benefits and risks are based in part on facts, but also on considerations of 
uncertainties about the facts, and on value judgements, including clinical relevance, of the facts. 
A key feature of decision modelling is its ability to distinguish facts from value judgements, and to 
combine both features into an overall assessment. Because value judgements are necessarily 
subjective, it is important to make them explicit and subject to discussion, debate and peer review. 
Even if agreement cannot be reached, a quantitative model can be used to explore whether or not 
disagreements matter to the final result. If they do, then further information or data might be 
required, or further exploration of the reasons for the disagreement surfaced. Always, whose values 
are to be considered is a key question: industry, regulator, prescriber or patient. Decision theory 
provides no answer other than a reminder that it is the decision maker whose values matter. Since 
decisions about drugs are made by all four of these decision makers, it is likely that they do not wholly 
share the same value judgements. Our focus is on regulators who are acting on behalf of an authority; 
presumably, then, it is the authority’s values that are being brought to bear on the benefit-risk 
balance. 
4.1.  Process features 
The process described in this report helps to create a context that enables useful and constructive 
interaction between key players in the decision making process. We see this as the result of eight 
features: 
First, the PrOACT-URL framework provides a process for developing amongst a group of key players a 
shared understanding of the issues, a sense of common purpose, and a commitment to the best way 
forward. 
Second, making the structure of a benefit-risk problem explicit, in the form of agreed options, an 
effects tree of objectives and criteria, and criteria definitions, ensures that everyone understands the 
meaning of the key elements of a benefit-risk assessment. The effects tree is a structure that provides 
information by the way the criteria are clustered under higher-level objectives. Criteria within a cluster 
are more similar than those between clusters, usually because all the criteria within a cluster are 
different ways of realising the higher-level objective represented by the node. Just seeing the overall 
organisation provides information to decision makers even before data are input. 
Third, clustering criteria assists in the assessment of weights. It is easier to compare similar criteria to 
each other first, then to take the most heavily-weighted criteria, one from each cluster, and compare 
them to each other. The structure also facilitates paired-comparisons rather than having to think of 
many criteria at the same time. 
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Fourth, clustering makes it easier to carry out consistency checks. Swing weights represent added 
value, so sums of swing weights should be meaningful to participants. For example, if criteria A, B and 
C are assigned swing weights of 100, 70 and 30, then the added value from least to most preferred 
positions on scales B and C should together equal the added vale on criterion A. We frequently asked 
these questions, which often resulted in scaling the non-100 weights downward. Without those 
consistency checks, there is a tendency to think everything is important, and thus to over-weight the 
criteria. 
Fifth, the goal of realism and consistency in scoring, developing value functions and assessing weights, 
pervades the process. The facilitator’s questions to the group are often in aid of this goal, whether it is 
seeking agreed definitions about effects, or making consistency checks in weighting. 
Sixth, using computer technology to reassemble the individual constituent parts into an overall result, 
and to explore differences of opinion and the effects of uncertainty, with instant playback of results in 
easily interpretable graphic displays, extends the capability of assessors to construct an informed 
judgement about the benefit-risk balance.  
Seventh, the facilitator’s impartiality provides a climate in which information is seen as a neutral 
commodity so that values can be safely explored 9. In particular, the facilitator guides the model-
building, attends to the group process and maintains a task orientation for the group, but does not 
contribute to the content of the discussion, thereby maintaining his or her impartiality. 
Eighth, the decision conference format, in which the model is constructed on-the-spot using specialised 
software that utilises a variety of graphical displays of results, immerses participants in every phase of 
the work. The result is that they gain a deep understanding and ownership of the results, which can be 
more nuanced even for simple models than any one individual’s understanding of the benefit-risk 
issues. 
4.2.  Observations 
In this section we report several observations that are indirectly relevant to benefit-risk assessment of 
drugs. However, the observations are limited by the potential unrepresentativeness of the five drugs 
we modelled, so we can at best only propose some working hypotheses. 
For some of the five drugs, participants reflected on the consistency of their judgements with previous 
cases. When value functions were elicited, participants sometimes wondered whether the same value 
function would apply in the future for new drugs. We do not know the answer to this question, but it 
should emerge as drug-specific value functions are created in the future. 
Do we think that generic models could emerge to be plucked off the shelf for a new drug? Surely there 
is no single generic model, for the five models reported here have little in common, other than the 
infections criterion. But we anticipate that models for a particular disease state may emerge as being 
so similar that a single model, consisting mostly of common criteria, but with provision for new criteria, 
could be helpful. 
It is interesting to see that the robustness of a model depends mainly on weights for unfavourable 
effects, but not for favourable effects. This is not surprising, as clinical studies are powered for the 
favourable effects, so the major uncertainties are in the unfavourable effects. At this stage, the 
dependence of robustness exclusively on unfavourable effects is no more than a working hypothesis, to 
be confirmed, or not, in subsequent research. 
Another working hypothesis is that the reason participants liked the Difference Display better than the 
Added-Value graph is that the former provides a better match to the mental model of assessors. 
Several assessors whom we interviewed in the first year of the Benefit-Risk Project explained that their 
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mental model starts with an expectation about a new drug that is determined by the therapeutic area, 
higher for areas in which available drugs are already successful, but lower for drugs dealing with very 
difficult conditions. That starting point serves as an initial anchor, which is then adjusted as assessors 
compare the drug with the placebo one effect at a time, first building up a reasonably positive picture 
from the primary and secondary endpoints, then feeling the balance become less good as the 
unfavourable effects are considered. This ‘anchoring-and-adjustment’ strategy has been noted in 
several psychological studies, often with the finding that people’s adjustments as more data become 
available are insufficient 10-11.  
We realised only at the fourth session the importance of exploring scenarios in which the impact of 
possible future events is explored. Past experience suggests that combinations of changes involving 
input scores, value functions and criterion weights can simulate possible future developments, such as 
unanticipated effects and their consequences, or the effects of a risk management plan. Thus, the 
model does not have to just represent a drug as it is now for the intended population; it can also be 
used to anticipate possible futures. 
These five cases only required application of decision theory, guided by the PrOACT-URL framework, to 
deal with the uncertainty and utilities of favourable and unfavourable effects. They did not require 
application of any of the other methodologies, probabilistic simulation, Markov processes, Kaplan-Meier 
estimators, QALYS or conjoint measurement, which we suggested in our Work Package 2 report might 
be useful. We still believe there is scope for these, but none of the five live cases we have looked at so 
far would have benefitted from these additional approaches. 
One exception is probabilistic simulation, for which we see an important long-term role. In each of the 
five cases, statistical summaries of central tendency formed the inputs for some of the criteria, and we 
used limits of confidence intervals as inputs in sensitivity analyses to test the robustness of model 
results. We believe that could become routine, but confidence intervals are only statements about 
standard errors of the statistic in question; they do not encompass the entire range of data in clinical 
studies. By treating the difference between favourable and unfavourable effects as an uncertain 
quantity, probabilistic simulation could show the distribution of people in the population over that 
uncertain quantity. That distribution would provide the simple statistic of the proportion of people for 
whom the benefits of the favourable effects exceed the severity of the unfavourable effects. 
We commented earlier on the many specialised scoring systems that have been developed for 
particular disease states. These systems typically consist of multiple criteria, sometimes combined in 
complex ways to provide a single score for a patient. These are, in effect, multi-criteria systems, 
developed without necessarily applying the formalities of multi-criteria decision analysis, as formulated 
in 1976 by Keeney and Raiffa 12, with the result that some are flawed. The same could be said of 
QALYs, which were mainly developed by health economists seeking a common unit of benefit so that 
cost-effectiveness could be compared across different disease states. The models developed in our five 
field tests are entirely consistent internally, in the sense that the weighting process ensures the 
equality of preference values across all the effects, but the scales are not comparable across the five 
models. It is our belief that regulators will need to continue using scoring systems developed by 
experts in disease states, but that these will continue to be incompatible with the QALY-based 
approach of health economists. 
However, we see a possible bridge between regulators and HTAs. A quantitative model developed by a 
regulator could be passed on to an HTA, who could add cost and QALY criteria. Once a trade-off is 
judged between a unit of benefit in the regulator’s model and a QALY, all the benefits in the regulator’s 
model can be expressed in units of QALYs and then the cost effectiveness calculation can proceed. In 
practice, this will be more complex than we suggest, but at least the outline of an improved working 
relationship between regulators and HTAs is worth exploring. 
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4.3.  Limitations 
All decision making, whatever the topic, is characterised by a trade-off between quality and effort. We 
devote more resources, intellectual, physical and emotional, to decisions whose consequences really 
matter to us. It is clear that this trade-off is exercised in regulatory decision making: more effort is 
typically expended in assessing the benefit-risk balance for new, innovative drugs that deal with life-
threatening conditions than for ‘me-too’ drugs for non-life-threatening diseases. Quantitative modelling 
is certainly not required for every new drug application—any improvement in quality might be so small 
that it would not justify the effort required to develop a model. Our study has not identified when 
quantitative modelling would be appropriate; the five cases were in part chosen under the judgement 
by an Agency’s assessors that these were suitable candidates for quantitative modelling, so we feel it 
would be premature to suggest when quantitative modelling would in general be appropriate. 
Guidelines for choosing to model or not will only emerge with experience and with follow-through of 
cases in which modelling was carried out. 
Neither does this study of five drugs answer the related question of how much modelling, simple or 
complex, would be useful to regulators. Again, the answer will emerge with experience, as we indicate 
in items 1 through 3 of our recommendations in the next section. It is clear to us that the PrOACT-URL 
framework would be helpful in assessing any new drug without developing a quantitative model. 
Criticisms occasionally arise that quantitative modelling is resource intensive. The assumption behind 
this criticism appears to arise from several previous attempts to apply MCDA to benefit-risk 
assessment with groups of assessors 13-14. In all these cases, the assessors either created a case on-
the-spot, or were given a write-up of a case study which they had not seen before. For our five 
models, all participants were well acquainted with the drug in question, and had in some way 
participated in writing at least a draft of the Day-80 Assessment Report. Thus, they were already clear 
about the options, and had a good sense of which effects were most important. That enabled us to 
structure the problem very quickly, and enabled a complete model to be thoroughly explored in just a 
single day.  
Previous experience using decision-analytic modelling with various pharmaceutical companies confirms 
that with experience, the level of effort required to complete a benefit-risk model approximately halves 
once participants know what to expect. In advance of a facilitated modelling session the participants 
can ensure that the options are agreed, that only criteria likely to affect the benefit-risk balance are 
included and that definitions and measurement scales are identified. Even entering the objective data 
could be done before the group meets. That leaves the task of briefing the group on work to date and 
then devoting the meeting to creating value functions, expressing clinical judgements in weighting and 
conducting sensitivity analyses.  
Another limitation of our study is that we did not record the assessors’ justifications for their clinical 
judgements. We have only recorded the value functions and weights in numerical form. Although the 
Hiview software provides a facility for annotating any inputs with text explanations, we did not have 
time to do this with our five groups. When this has been done in the past, the facilitator pauses after 
each set of judgements (e.g., the weights on all criteria below a chosen node) and asks the group to 
provide the reasons for those judgements. That can add an hour or two to sessions in which 10 to 15 
criteria and three to five options are included in the model. This approach could save time 
subsequently as model results are transferred into text (e.g. for the EPAR). It would also decrease 
subsequent challenges because the reasoning is now apparent, although in some cases could increase 
debate as others disagree with the original assessors’ opinions. But that at least would open up 
discussion on important issues that might otherwise have remained unaddressed. Here, again, the 
quality-effort trade-off has to be judged separately for each case. 
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A final limitation is inherent in the available software. Decision-analytic software generally falls into two 
categories: those modelling uncertainty will use decision trees and influence diagrams, with limited 
ability to represent multiple objectives, while those modelling multiple objectives use value trees with 
limited capabilities for incorporating uncertainty. Hiview falls into the latter category, and we managed 
uncertainty in three ways: by using measures of central tendency as inputs for some criteria (so 
distributions of uncertain quantities have been summarised by measures such as a mean, which 
accommodates the uncertainty), by carrying out sensitivity analyses on uncertain quantities (e.g., 
varying a weight over its entire range, or using the upper/lower limits of confidence intervals as input 
scores) and by exploring scenarios (e.g., combinations of different scores and weights) to anticipate 
the results of uncertain future developments. We believe that further development of software would 
make benefit-risk modelling easier and more routine. Indeed, software could be developed for use by 
assessors who have no knowledge of decision theory or MCDA, though it would be important to design 
the software in such a way that it can be interrogated easily to see why results were obtained, thus 
avoiding the ‘black box’ syndrome. 
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5.  Conclusions 
We return, now, to the purpose of the Benefit-Risk Project: the development and testing of tools and 
processes for balancing multiple benefits and risks, which can be used as an aid to informed, science-
based regulatory decisions about medicinal products. The requirement to be ‘science-based’ suggests 
that the regulatory decisions should be guided by explicit problem-solving and decision-making 
processes. We field tested a combination of three processes, the PrOACT-URL framework, decision-
analytic modelling and facilitated workshops, and found that their collective application could indeed 
aid regulatory decision making. Deliverables for Work Package 3 consisted of a report of each field test 
“summarising the exercise and identifying those processes, tools and organisational structures that 
were considered to add value to the process of benefit-risk assessment by regulatory authorities”. 
Those reports have been completed and approved. 
To identify the features that added value, the pre- and post-session questionnaires included most of 
the questions we had proposed for Work Package 4, whose purpose is to develop benefit-risk tools and 
processes. The WP4 deliverables include an operational decision-aid, and a consultative workshop “to 
explore the acceptability and the potential implementation of the tools and processes”. The further 
development of both could easily take place over the next few months in two stages: develop an 
operational decision aid by the end of 2011, then hold a public consultation and workshop in the first 
half of 2012. 
The success of the five field tests raises issues for the EMA/CHMP about endorsing the three processes 
we applied in the facilitated group modelling as a useful adjunct to its current processes. These 
include: 
1. Adopting the PrOACT-URL framework to guide the process of evaluating the benefit-risk balance. It 
could be left to the Rapporteur and Co-Rapporteur to decide how the framework should be applied 
to any specific drug. In some cases, once the nature of the problem and its context, the options to 
be assessed and all effects -- favourable and unfavourable -- have been identified, the solution 
may be so obvious that no further steps are required. If not, then providing a Consequence Table, 
with the options in columns, the criteria as rows, and quantitative and qualitative outcomes in the 
cells, may be sufficient to see a solution. If further work is required, then successive stages might 
benefit from a quantitative model. 
2. Developing a simple quantitative model. The simplest quantitative model replaces the cells in the 
Consequence Table with preference values that are linearly related to the measures shown in the 
cells of each row. Weights are then assigned to the scale ranges in each row. Weighted scores are 
calculated for each cell, and the weighted scores summed in each column, with the totals showing 
the overall added value for the options. Simple and effective, anybody can learn it. It is clearly 
explained in Chapter 6 of Multi-Criteria Analysis: A Manual 15 
(http://www.communities.gov.uk/documents/corporate/pdf/1132618.pdf). 
3. Developing a more complex model. If a simple model does not adequately represent the 
complexity of the problem (e.g., the assumption of linearity between preference values and 
measured data is violated) a more comprehensive model, like that for Drug X, could be developed 
with the support of appropriate decision-analytic software. 
4. Applying quantitative modelling as a once-off exercise, or as a continuous process. Modelling could 
be applied at any stage of the 210-day process, though not before assessors and other experts 
have at least gained a degree of familiarity with the dossier. A model could assist regulators in 
preparing the Day-80 report, or in consolidating the subsequent assessment reports as more 
information is obtained. It could even be used in post-approval monitoring. 
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5. Encouraging applicants to develop quantitative models to clarify the benefit-risk balance. 
Companies could be encouraged to submit benefit-risk models in support of their application, as 
some are already doing. Assessors would then be in a better position to judge the benefit-risk 
balance because a model makes explicit the many pieces of the benefit-risk puzzle, providing a 
clear view of how adequately each piece contributes to the overall result. Of course, this also 
imposes a duty of care on the assessors to understand the model so they can make valid 
comments on it. Lacking that expertise, as must have been the case in the early days when 
statistical analyses were not well understood by assessors, special training programmes will be 
required for assessors to provide them with sufficient information about benefit-risk models. Of 
course the purpose of statistical modelling is to obtain a view that is as objective as possible. 
Benefit-risk assessment additionally requires and makes value judgements explicit, and the ideal 
application would show that the benefit-risk balance is robust to differences in those value 
judgements. This would enable the CHMP to challenge, if necessary, those value judgements that 
are the crucial ones in making the final recommendation and not spend time on those judgements 
that change the benefit-risk balance insufficiently to make a difference to the recommendation.  
6. Using quantitative models during CHMP meetings. This would provide a very rapid means for the 
Rapporteur to brief the meeting on the benefit-risk issues, and it could help members resolve 
differences of opinion about matters that have been modelled. The model could facilitate the 
process of turning quantitative results back into words that provide a clear justification for the 
benefit-risk assessment in the EPAR and other documents. Indeed, the development of requisite 
decision models 16 was motivated by the finding that final decisions did not always align to model 
results. In fact, it was when they did not align that decision makers found the modelling most 
helpful. This was because the model provided a framework for clear and rational thinking and a 
structure for constructive dialogue. As a result the modelling process helped to develop new 
insights, realigning intuitions and creating a sense of common purpose among participants. In 
short, it is the process of modelling, not necessarily the result, from which decision makers mainly 
derive benefit. 
7. Providing training in the PrOACT-URL framework and in decision-analytic modelling. Two levels of 
training would be appropriate: an overview and introduction whose purpose is only to acquaint 
participants with the framework and the models, sufficient to enable them to understand results, 
and intensive training for those who wish to be able to guide others in using the framework and in 
doing the modelling. 
8. Using the modelling to facilitate justification of the benefit-risk assessment. The modelling process 
of peer review and interacting with the model can deepen insight about the benefit-risk balance, 
which helps participants to form clear preferences about a drug’s effects. This should facilitate the 
preparation of a clear justification for the benefit-risk assessment, especially in the EPAR. It should 
be possible to monitor and compare EPARs that have benefitted from the modelling process with 
those that have not to establish whether or not modelling has improved the communicability of 
benefit-risk assessment. 
It is worth once again stressing that the role of a framework is simply to provide a guide, rather like 
the check-list that is now widely used in surgical operations. And the role of a model is to provide a 
tool to aid thinking; it does not do the thinking and it does not give the ‘right’ answer. It simply feeds 
back to participants the logical consequences of the data and clinical judgements that have been given 
to it. The model is rather like another participant, but one that does not talk back; it simply reflects 
back what it has been told, but in changed form. The computer requires human judgement to tell it the 
favourable and unfavourable effects, the input data, the judgements in the form of value functions and 
weights, then, no matter how large the problem, it unfailingly provides the logical consequences of 
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those inputs, thereby overcoming human limitations on the amount of information we can process 17 in 
our heads. 
But that is not the end of the process. Participants may well feel uneasy about the displayed results. In 
a facilitated workshop, the next step is to explore the discrepancy between intuitions and computer 
results. By doing so, new insights inevitably develop, demonstrating that the computer is wrong, or 
that intuitions need to be changed or informed. With new insights, changes are made to the model or 
to intuitions, results examined, intuitions challenged again. After several iterations of this process a 
‘requisite model’ 16 emerges—sufficient in form and content to resolve the benefit-risk issues. At this 
point, the group is much clearer about what recommendations to make, and they can turn the results 
of the requisite model into words, sometimes supported by graphs from the model output. (For 
reporting purposes, four displays seem to be sufficient: the Effects Tree, the Effects Table, the Added-
Value Bar Graph and the Difference Display.) It is even possible for the group to reject the model’s 
results; often, these are the models a group has found to be most helpful, because it gave results that 
challenged thinking, which led to new insights and perspectives that allowed members of the group to 
agree on the way forward. 
In short, the work reported here is to serve as an aid to informed, science-based regulatory decisions 
about medicinal products. It is intended to supplement and enhance human capability to deal with 
complex issues.  
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Appendix—The PrOACT-URL process 
1. PrOBLEM. Determine the nature of the problem and its context: what is the medicinal product 
(e.g., new or marketed chemical or biological entity, device, generic); what sort of decision or 
recommendation is required (e.g., approve/disapprove, restrict); who are the stakeholders and key 
players; what factors should be considered in solving the problem (e.g., the therapeutic area, the 
unmet medical need, severity of condition, life-threatening or not, affected population, an 
individual’s social context, time frame for outcomes). Then frame the problem (e.g., as mainly a 
problem of uncertainty, or of multiple conflicting objectives, or as some combination of the two). 
2. OBJECTIVES. (Steps 2 and 3 are interchangeable in order.) Identify objectives that indicate the 
overall purposes to be achieved (e.g., maximise favourable effects, minimise unfavourable effects), 
and develop criteria against which the alternatives can be evaluated (i.e., what are the favourable 
and unfavourable effects?). Establish measurement scales for all criteria. 
3. ALTERNATIVES. Identify the options (actions about a medicinal product or the products 
themselves) to be evaluated against the criteria (e.g., pre-approval: new treatment, placebo, 
active comparator, dosages; post-approval: do nothing, limit duration, change dosage, restrict 
indication, suspend). 
4. CONSEQUENCES. Based on available data, describe how the alternatives perform on the criteria, 
i.e., describe the magnitude of possible favourable and unfavourable effects. It may be helpful to 
consider intermediate outcomes, such as safety and efficacy effects. Describe the clinical relevance 
of the effects, effectiveness and frequency of favourable effects, and severity and incidence of 
unfavourable effects. Create an ‘Effects Table’ with alternatives in columns and criteria in rows. 
Write descriptions of the effects in each cell, qualitative and quantitative (including statistical 
summaries with confidence intervals). It may at this stage be helpful to record the basis for 
uncertainties about the consequences in preparation for step 6 (e.g., possible biases in the data, 
soundness and representativeness of the clinical trials, potential for unobserved adverse events), if 
relevant. 
5. TRADE-OFFS. Assess the balance between favourable and unfavourable effects. 
These five steps are common to all decisions in which the consequences are known with certainty. In 
approving drugs, regulators typically must face uncertainty and risk, in which case three additional 
steps are relevant: 
6. UNCERTAINTY. Consider how the balance between favourable and unfavourable effects changes 
by taking account of the uncertainty associated with the consequences. 
7. RISK ATTITIDE. Judge the relative importance of the Agency’s risk attitude for this medicinal 
product (by considering, e.g., the therapeutic area, the unmet medical need, life-threatening or 
not, affected population and patients’ concerns) and adjust the uncertainty-adjusted balance 
between favourable and unfavourable effects accordingly. Consider, too, how risks would be 
perceived by stakeholders (according to their views of risk). 
8. LINKED DECISIONS. Consider the consistency of this decision with similar past decisions, and 
assess whether taking this decision could impact future decisions either favourably or unfavourably 
(e.g., would it set a precedent or make similar decisions in the future easier or more difficult). 
 
 
